Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2505-2512

  Geisler, Stephanie ^a   Lønning, Per Eystein ^a   Aas, Turid ^a   Johnsen, Hilde ^b   Fluge, Øystein ^a   Haugen, Dagny Faksvåg ^a   Lillehaug, Johan Richard ^a   Akslen, Lars Andreas ^a   Børresen Dale, Anne Lise ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C ERB2 PROTEIN; DOXORUBICIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 0035866772     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Steroid receptors in human breast cancer
2. Apoptosis. Its significance in cancer and cancer therapy
3. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
4. p53 Status and the efficacy of cancer therapy in vivo
5. p53 Protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
6. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
7. p53 Immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer
8. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
9. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer
10. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression
11. p53 Expression and the result of adjuvant therapy of breast cancer
12. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2, and GST pi
13. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
14. Predictive value of c-erbB-2, p53, cathepsin-D, and histology of the primary tumor in metastatic breast cancer
15. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
16. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
17. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
18. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
19. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma
20. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced nonsmall cell lung cancer
21. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
22. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer
23. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus
24. p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis
25. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
26. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
27. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases
28. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
29. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
30. Multidrug resistance in breast cancer - Is the jury in yet?
31. Multidrug resistance in breast cancer: A meta-analysis of MDRI/gpl70 expression and its possible functional significance
32. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells
33. The biology of erbB-2/neu/HER-2 and its role in cancer
34. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
35. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer
36. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
37. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
38. Assessment of response to therapy in advanced breast cancer
39. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas
40. Temporal temperature gradient gel electrophoresis using the Dcode system
41. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene
42. Detection of loss of the human TP53 locus using a dinucleotide repeat polymorphism
43. Expression of c-erbB-2 protein in papillary thyroid carcinomas
44. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
45. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis
46. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
47. p53 Immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results
48. Prediction of response to primary chemotherapy for operable breast cancer
49. p53 Genotype and major response to anthracyclin or paclitaxel based neoadjuvant treatment in breast cancer patients
50. p53 Gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer
51. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy
52. Specific DNA binding by different classes of human p53 mutants
53. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
54. In vitro analysis of the dominant negative effect of p53 mutants
55. Specific binding of MAR/SAR DNA-elements by mutant p53
56. Gain of function mutations in p53
57. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
58. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
59. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer
60. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
61. Efficacy and safety of herceptintm (trastuzumab, humanized anti-her2 antibody) as a single agent in first-line treatment of her2 overexpressing metastatic breast cancer (her2+/mbc)
62. Double identity for proteins of the Bcl-2 family
63. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer - A pilot study
64. A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis
65. Down-regulation of bcl-2 by p53 in breast cancer cells